Tammen Alison J, Brescia Donald, Jonas Dan, Hodges Jeremy L, Keith Philip
22500Community Hospital North, Indianapolis, IN, USA.
427363Novant Health Presbyterian Medical Center, Charlotte, NC, USA.
J Intensive Care Med. 2023 Feb;38(2):196-201. doi: 10.1177/08850666221115635. Epub 2022 Jul 19.
Opioid induced chest wall rigidity was first described in the early 1950s during surgical anesthesia and has often been referred to as fentanyl induced rigid chest syndrome (FIRCS). It has most commonly been described in the setting of procedural sedation and bronchoscopy, characterized by pronounced abdominal and thoracic rigidity, asynchronous ventilation, and respiratory failure. FIRCS has been infrequently described in the setting of continuous analgesia in critically ill adult patients. We postulate that FIRCS can occur in this setting and is likely under recognized, leading to increased morbidity and mortality.
Patients admitted to the intensive care unit with suspected FIRCS were included in this retrospective analysis. The objective of this analysis is to describe the clinical presentation and treatment strategies for FIRCS.
Forty-two patients exhibiting symptoms of FIRCS were included in this analysis. Twenty-two of the forty-two patients with descriptive documentation had evidence of thoracic or abdominal rigidity on examination (52.4%). Twelve of sixteen (75%) patients treated solely with naloxone had documented ventilator compliance following intervention, compared to six of eleven (55%) managed with cisatracurium alone. Nine of twelve patients who ultimately received naloxone after initial treatment with cisatracurium had documented ventilator compliance following naloxone administration (75%). Standard interventions, including sedation optimization and ventilator adjustments were attempted to rule out and treat other potential causes of dyssynchrony. In most cases, the administration of naloxone resulted in appropriate compliance with both ventilator and patient-initiated breaths, suggesting the ventilator dyssynchrony was due to fentanyl.
This is the largest case series to date describing FIRCS in the intensive care setting. Recognition and prompt management is necessary for improved patient outcomes. Research is needed to increase awareness and recognition, identify patient risk factors, and analyze the efficacy and safety of interventions.
阿片类药物诱发的胸壁强直于20世纪50年代初在外科麻醉期间首次被描述,常被称为芬太尼诱发的僵硬胸综合征(FIRCS)。它最常见于程序性镇静和支气管镜检查时,其特征为明显的腹部和胸部强直、不同步通气及呼吸衰竭。FIRCS在危重症成年患者持续镇痛的情况下鲜有描述。我们推测FIRCS可发生于这种情况下,且可能未得到充分认识,从而导致发病率和死亡率增加。
本回顾性分析纳入了入住重症监护病房且疑似患有FIRCS的患者。该分析的目的是描述FIRCS的临床表现及治疗策略。
本分析纳入了42例出现FIRCS症状的患者。42例有描述性记录的患者中,22例在检查时有胸壁或腹壁强直的证据(52.4%)。仅接受纳洛酮治疗的16例患者中有12例(75%)在干预后记录到通气机顺应性改善,而仅接受顺式阿曲库铵治疗的11例患者中有6例(55%)通气机顺应性改善。12例最初接受顺式阿曲库铵治疗后最终接受纳洛酮治疗的患者中有9例(75%)在给予纳洛酮后记录到通气机顺应性改善。尝试了包括优化镇静和调整通气机等标准干预措施以排除和治疗其他不同步的潜在原因。在大多数情况下,给予纳洛酮可使通气机和患者自主呼吸均达到适当的顺应性,提示通气机不同步是由芬太尼所致。
这是迄今为止描述重症监护环境下FIRCS的最大病例系列。为改善患者预后,识别并及时处理至关重要。需要开展研究以提高认识和识别能力、确定患者危险因素并分析干预措施的有效性和安全性。